PreciseDx, the leading innovator behind PreciseBreast, a novel breast cancer diagnostic that is powered by OncoIntelligence, their proprietary AI-platform, announced the successful closing of $11 million in funding and two key leadership hires.

This latest round of funding was led by Eventide Asset Management, Merck Global Health Innovation Fund and Philips Ventures and included Labcorp, Quest Diagnostics, GenHenn Capital Venture, along with other existing investors. This funding will help prioritize the company's ongoing clinical data collection, commercial expansion and planning for the 2026 launch of its flagship product, PreciseBreast.